NEWS & EVENTS

  • December 15, 2011FDA Will Not Require a Risk Evaluation and Mitigation Strategy in Connection With Corcept's Proposed Distribution of Korlym™ for Cushing's Syndrome READ MORE
  • November 2011Availability Of Mifepristone Through A Compassionate Use ProgramREAD MORE

FOR

PATIENTS

Corcept is dedicated to the development of treatments for the severe diseases caused by excess or irregular cortisol levels. Our most advanced programs are for the treatment of Cushing’s Syndrome and for psychotic depression.

READ MORE

DEVELOPMENT

PROGRAMS

Our development programs are focused on the treatment of diseases in which cortisol plays a role. Our lead programs are for the treatment of Cushing's Syndrome and psychotic depression.

READ MORE